Subscribe
istock-183060916
oonal / iStockphoto.com
20 July 2018Biotechnology

Novartis signs antibody licensing agreement with two biotechs

Novartis has signed a global licensing agreement with two biotechnology companies centring on the development of an antibody treatment for inflammatory skin conditions.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Gilead enters $5bn R&D deal with Galapagos
16 July 2019   Gilead will pay more than $5 billion as part of a collaborative research and development agreement with Belgian-Dutch pharmaceutical company Galapagos.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Big Pharma
Gilead enters $5bn R&D deal with Galapagos
16 July 2019   Gilead will pay more than $5 billion as part of a collaborative research and development agreement with Belgian-Dutch pharmaceutical company Galapagos.

More on this story

Big Pharma
Gilead enters $5bn R&D deal with Galapagos
16 July 2019   Gilead will pay more than $5 billion as part of a collaborative research and development agreement with Belgian-Dutch pharmaceutical company Galapagos.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims